CD74

VIENNA--(BUSINESS WIRE)-- OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104. ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases. “The growing amount of preclinical data for ON104 is very promising and illustrates its broad applicability in key indications such as RA, inflammatory bowel disease, asthma, and nephritis,” commented Randolf Kerschbaumer, Ph.D., CEO of OncoOne. “As we continue to validate our technology’s ability to effectively neutralize disease progression in autoimmune diseases, this board of distinguished experts will be invaluable to the clinical strategy for ON104 and will support OncoOne’s vision of supplying a new class of therapeutic solutions to patient populations with a high unmet medical need.” The members of the OncoOne Clinical Advisory Board include: Richard Bucala, M.D., Ph.D. Richard Bucala, is the Chief of Rheumatology, Allergy & Immunology at the Yale Institute for Global Health and the Waldemar Von Zedtwitz Endowed Professor of Medicine, Pathology, Epidemiology, & Public Health at the Yale School of Medicine. Dr. Bucala is renowned in MIF research and is recognized for discovering MIF's receptor CD74, as well as elucidating MIF's critical role in regulating glucocorticoid immunosuppression. He is an attending physician in the Yale New Haven Health System and is the past Editor-in-Chief of Arthritis & Rheumatology. Dr. Bucala was elected to the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP), in addition to having served on an advisory board for the United Nations and various other U.S. federal, academic, and pharmaceutical organizations. Daniel Aletaha, M.D. Daniel Aletaha is Professor and Head of the Clinical Department of Rheumatology at the Medical University of Vienna. Dr. Aletaha is the current president of the European Alliance of Associations for Rheumatology (EULAR). His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases. He has experience in the areas of novel therapies and treatment strategies, diagnosis, prognosis, outcomes, and biomarkers. He currently holds over 350 indexed publications. Seamas Donnelly, M.D. Dr. Seamas Donnelly is a Professor of Medicine at Trinity College Dublin. He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies. He has authored many MIF-focused publications in renowned peer-reviewed journals, including Nature Medicine and Molecular Medicine. Dr. Donnelly’s research epitomizes classical bench to bedside on an international scale, and, in recognition of this, has been awarded an Honorary Professorship in Translational Medicine by the University of Edinburgh. He is the current President of the Association of Physicians of Great Britain & Ireland, the leading academic medical association in the UK and Ireland. Dr. Donnelly is also the lead Trinity PI of Health Innovation Hub Ireland and has been a member of OncoOne’s scientific advisory board since 2022. Michael Freissmuth, M.D. Dr. Freissmuth is the Director of the Center of Physiology & Pharmacology as well as the Chairman of the Institute of Pharmacology at the Medical University in Vienna. He was appointed Professor of Pharmacology in 1995 and received many awards, including the Novartis Award for Medicine. Dr. Freissmuth is a member of numerous editorial boards and serves on several review panels and scientific advisory boards. His most recent appointments include positions on international panels such as the Scientific Advisory Board of the Institut Cochin de Génétique Moléculaire in Paris and of the Engelhorn Foundation for Life Sciences. He is also a member of the supervisory board of Boehringer Ingelheim Austria. Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics. About OncoOne OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF). The Company is focused on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of cancer, as well as for chronic inflammatory diseases. Equipped with a successful track-record in early-stage drug development, as well as a deep understanding of the target itself, OncoOne’s leadership will advance a pipeline based on oxMIF’s promise in inflammation and other disease areas. View source version on businesswire.com: Contacts For OncoOne: Randolf Kerschbaumer, Ph.D., CEO Website: E-mail: contact@oncoone.com Phone: +43 1 909 2208 - 6000 For Media Inquiries: Trophic Communications Desmond James E-mail: OncoOne@trophic.eu Phone: +49 1516 7859086 Source: OncoOne View this news release online at:

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms. “Dr. Gerber’s deep experience in the development of ADCs and other novel therapeutics make him an invaluable addition to our management team,” said Bill Newell, Sutro’s Chief Executive Officer. “With a demonstrated track record from target identification and selection of lead compounds to IND and subsequent regulatory filings, he is the ideal CSO for Sutro. As we continue to develop our pipeline, Dr. Gerber is well-positioned to execute on our goal of continuing to identify, design, and develop next-generation cancer drugs that will rapidly progress into the clinic.” “I was impressed by Sutro’s unique ability to design and manufacture precise targeted molecules, addressing current challenges in the development of biotherapeutics, as well as its already promising pipeline,” said Dr. Gerber. “It is an honor to join such a talented team and to have the chance to transform the lives of cancer patients by discovering and developing innovative treatments.” Dr. Gerber began his Biotech career at Genentech in the Department of Molecular Oncology, followed by various management roles at Seattle Genetics and Pfizer. He has a strong track record in leading cross-functional teams, innovative discovery and translational medicine, and contributions to IND filings and BLA submissions. Prior to joining Sutro, Dr. Gerber served as Chief Scientific Officer at Codeable Therapeutics, an ADC startup company focusing on the development of next generation ADCs that induce immunogenic cell death. Previously, he held executive roles at 3T Biosciences and Maverick Therapeutics. He has also served as an advisor for various Biotech startups, VCs, and Pharma companies and is currently a Board member at Athebio AG and Chairman of the Board at T-CURX. With over 100 peer-reviewed publications and 100 issued patents, he has an impressive record of high scientific achievement. He received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) In connection with Dr. Gerber’s appointment as Chief Scientific Officer, the Compensation Committee of Sutro’s Board of Directors granted to Dr. Gerber 175,000 shares of Sutro stock options and 150,000 restricted stock units (RSUs) of Sutro common stock. These grants were made as an inducement material to the Dr. Gerber’s acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs and stock options are subject to the terms and conditions of Sutro’s 2021 Equity Inducement Plan. One-fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the Dr. Gerber’s hire date and annually thereafter until fully vested on the fourth anniversary, subject to Dr. Gerber’s continued service with Sutro on each such vesting date. One-fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of Dr. Gerber’s hire date and 1/48th of the total number of shares underlying the stock options will vest each month thereafter until fully vested on the fourth anniversary of Dr. Gerber’s hire date, subject to Dr. Gerber’s continued service with Sutro on each such vesting date. The stock options have a term of ten years and an exercise price equal to the closing price of Sutro’s common stock on the grant date as reported by The Nasdaq Stock Market. About Sutro Biopharma Sutro Biopharma, Inc., is a clinical-stage company developing next-generation cancer therapeutics, principally antibody-drug conjugates (ADCs), designed for greater potency, tolerability and improved safety. Sutro’s cell-free technology, XpressCF®, enables the design and manufacture of homogeneous product candidates with precise and empirically-demonstrated positioning of linker-payloads and consistent drug antibody ratio (DAR). Sutro’s platform has produced six clinical stage candidates to date, including two wholly-owned ADCs—luveltamab tazevibulin, or luvelta, a folate receptor alpha (FolRα)-targeting ADC in clinical studies for ovarian and endometrial cancers, as well as STRO-001, a CD74-targeting ADC in clinical studies for B-cell malignancies. In addition, the Company has a robust pipeline of preclinical and discovery stage candidates including STRO-003, a ROR1-targeting ADC, and STRO-004, a tissue factor-targeting ADC. Sutro has also entered into high-value collaborations with industry partners, including Astellas and Merck (MSD outside of the United States and Canada); and Sutro’s platform technology enabled the formation of Vaxcyte. Sutro is headquartered in South San Francisco. For more information, follow Sutro on Twitter, @Sutrobio, or visit www.sutrobio.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results, trial initiation, and regulatory filings, potential benefits of luvelta and the Company’s other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for luvelta and the Company’s other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and the Company’s ability to successfully leverage Fast Track designation, the market size for the Company’s product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, the value of the Company’s holdings of Vaxcyte common stock, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. ContactEmily WhiteSutro Biopharma (650) 823-7681ewhite@sutrobio.com

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate: Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT Location: Boston 2023 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 7, 2023Time: 10:15 a.m. ET / 7:15 a.m. PT Location: Boston Webcasts of the fireside chats will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event. About Sutro Biopharma Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—luveltamab tazevibulin (STRO-002 or luvelta), a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology. ContactAnnie J. Chang Sutro Biopharma (650) 801-5728 ajchang@sutrobio.com